Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
NBY's Cash to Debt is ranked higher than
99% of the 1244 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. NBY: No Debt )
NBY' s 10-Year Cash to Debt Range
Min: 12.67   Max: No Debt
Current: No Debt

Equity to Asset 0.52
NBY's Equity to Asset is ranked higher than
64% of the 933 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NBY: 0.52 )
NBY' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.83
Current: 0.52

-0.32
0.83
Interest Coverage No Debt
NBY's Interest Coverage is ranked higher than
89% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NBY: No Debt )
NBY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -8.27
M-Score: 0.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1569.71
NBY's Operating margin (%) is ranked higher than
56% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. NBY: -1569.71 )
NBY' s 10-Year Operating margin (%) Range
Min: -445.38   Max: 17.47
Current: -1569.71

-445.38
17.47
Net-margin (%) -1385.18
NBY's Net-margin (%) is ranked higher than
56% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.55 vs. NBY: -1385.18 )
NBY' s 10-Year Net-margin (%) Range
Min: -461.37   Max: 17.2
Current: -1385.18

-461.37
17.2
ROE (%) -182.66
NBY's ROE (%) is ranked higher than
55% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NBY: -182.66 )
NBY' s 10-Year ROE (%) Range
Min: -699.25   Max: 26.07
Current: -182.66

-699.25
26.07
ROA (%) -106.72
NBY's ROA (%) is ranked higher than
54% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: -27.84 vs. NBY: -106.72 )
NBY' s 10-Year ROA (%) Range
Min: -426.46   Max: 17.13
Current: -106.72

-426.46
17.13
ROC (Joel Greenblatt) (%) -2780.29
NBY's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 1220 Companies
in the Global Biotechnology industry.

( Industry Median: -415.02 vs. NBY: -2780.29 )
NBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2673.41   Max: 139.97
Current: -2780.29

-2673.41
139.97
Revenue Growth (3Y)(%) -40.20
NBY's Revenue Growth (3Y)(%) is ranked higher than
62% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. NBY: -40.20 )
NBY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 36.1
Current: -40.2

0
36.1
EBITDA Growth (3Y)(%) 30.50
NBY's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NBY: 30.50 )
NBY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 58.2
Current: 30.5

0
58.2
EPS Growth (3Y)(%) 32.60
NBY's EPS Growth (3Y)(%) is ranked higher than
94% of the 732 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. NBY: 32.60 )
NBY' s 10-Year EPS Growth (3Y)(%) Range
Min: -33.1   Max: 56.5
Current: 32.6

-33.1
56.5
» NBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

NBY Guru Trades in Q2 2013

Jim Simons 15,200 sh (New)
» More
Q3 2013

NBY Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q2 2014

NBY Guru Trades in Q2 2014

Jim Simons 39,500 sh (New)
» More
Q3 2014

NBY Guru Trades in Q3 2014

Jim Simons 132,100 sh (+234.43%)
» More
» Details

Insider Trades

Latest Guru Trades with NBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.80
NBY's P/B is ranked higher than
74% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 6.37 vs. NBY: 5.80 )
NBY' s 10-Year P/B Range
Min: 1.76   Max: 13.86
Current: 5.8

1.76
13.86
P/S 32.00
NBY's P/S is ranked higher than
73% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 29.14 vs. NBY: 32.00 )
NBY' s 10-Year P/S Range
Min: 1.53   Max: 43.35
Current: 32

1.53
43.35
EV-to-EBIT -1.42
NBY's EV-to-EBIT is ranked higher than
54% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NBY: -1.42 )
NBY' s 10-Year EV-to-EBIT Range
Min: -34.8   Max: 81.4
Current: -1.42

-34.8
81.4
Current Ratio 4.43
NBY's Current Ratio is ranked higher than
72% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.71 vs. NBY: 4.43 )
NBY' s 10-Year Current Ratio Range
Min: 1.34   Max: 10.63
Current: 4.43

1.34
10.63
Quick Ratio 4.26
NBY's Quick Ratio is ranked higher than
72% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. NBY: 4.26 )
NBY' s 10-Year Quick Ratio Range
Min: 1.34   Max: 10.63
Current: 4.26

1.34
10.63

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.14
NBY's Price/Net Cash is ranked higher than
84% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 52.60 vs. NBY: 9.14 )
NBY' s 10-Year Price/Net Cash Range
Min: 2.65   Max: 17.2
Current: 9.14

2.65
17.2
Price/Net Current Asset Value 8.00
NBY's Price/Net Current Asset Value is ranked higher than
84% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 31.80 vs. NBY: 8.00 )
NBY' s 10-Year Price/Net Current Asset Value Range
Min: 2.3   Max: 15.64
Current: 8

2.3
15.64
Price/Tangible Book 5.81
NBY's Price/Tangible Book is ranked higher than
80% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. NBY: 5.81 )
NBY' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 12.29
Current: 5.81

1.9
12.29
Price/Median PS Value 6.40
NBY's Price/Median PS Value is ranked higher than
68% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 2.24 vs. NBY: 6.40 )
NBY' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 7.98
Current: 6.4

0.34
7.98
Earnings Yield (Greenblatt) -70.40
NBY's Earnings Yield (Greenblatt) is ranked higher than
50% of the 1217 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. NBY: -70.40 )
NBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 6.7
Current: -70.4

1.2
6.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
NovaBay Pharmaceuticals, Inc., was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc., and subsequently changed its name to NovaBay Pharmaceuticals, Inc. The Company is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct categories of products, Aganocides and NeutroPhase. The Company is focusing its Aganocide compounds into three large therapeutic markets: Urology - Statistically-significant and clinically-meaningful results from a Phase 2 clinical study of Auriclosene Irrigation Solution to reduce urinary catheter blockage and encrustation, Ophthalmology - NovaBay is developing an eye drop formulation of auriclosene (NVC-422) for treating adenoviral conjunctivitis, for which there is currently no FDA-approved treatment, Dermatology - Partnered with Galderma, a dermatology company, the Company is developing a gel formulation of auriclosene (NVC-422) for treating impetigo, a contagious skin infection. The Company has also developed NeutroPhase, a distinct class of molecule from the Aganocides. NeutroPhase is an FDA 510(k)-cleared Advanced Skin and Wound Cleanser. It has developed variations of the NeutroPhase product such as i-Lid Cleanser and CelleRx. The competitors for its Aganocides and for NeutroPhase include large and small pharmaceutical and medical device companies, such as Pfizer, Inc., Johnson & Johnson, Abbott Grp. Plc., GlaxoSmithKline Plc, Sanofi-Aventis SA, Novartis AG, Smith & Nephew Plc, C.R. Bard, Molnlycke, Lohman and Roucher, Johnson and Johnson, 3M, Puricore and Oculus Innovative Sciences. The Company's Aganocide product candidate, auriclosene (NVC-422), as well as many of the product candidates they expect to develop in the future. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of its product candidates are subject to extensive regulation by the FDA, state agencies and comparable regulatory authorities in other countries.
» More Articles for NBY

Headlines

Articles On GuruFocus.com
Own it Feb 29 2012 
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results Aug 14 2009 

More From Other Websites
NovaBay Executive Officers Report Insider Buying of 143,000 Common Shares to the SEC Dec 23 2014
Christmas Gift to People Worldwide Suffering From “Flesh Eating” Disease: NovaBay... Dec 23 2014
Christmas Gift to People Worldwide Suffering From "Flesh Eating" Disease: NovaBay Pharmaceuticals... Dec 23 2014
China Pioneer Pharma Joins Hand with NovaBay Pharmaceuticals and the NNFF To Offer Free New... Dec 19 2014
NovaBay Executive Officers Report Insider Buying of 143,000 Common Shares to the SEC Dec 16 2014
NovaBay Signs Distribution Agreement With the Biopharm Group Dec 08 2014
NovaBay Signs Distribution Agreement With the Biopharm Group Dec 08 2014
NovaBay’s i-Lid Cleanser Featured in Review of Optometry Dec 02 2014
NovaBay's i-Lid Cleanser Featured in Review of Optometry Dec 02 2014
NovaBay Pharmaceuticals will attend Annual LD MICRO Conference Dec 01 2014
NovaBay Pharmaceuticals will attend Annual LD MICRO Conference Dec 01 2014
White Paper Describes NovaBay’s Non-Antibiotic Anti-infective Portfolio Nov 24 2014
White Paper Describes NovaBay’s Non-Antibiotic Anti-Infective Portfolio Nov 24 2014
NovaBay’s NeutroPhase Cleared for Sale by Taiwan FDA Nov 18 2014
NOVABAY PHARMACEUTICALS, INC. Financials Nov 18 2014
NovaBay Signs Distribution Agreement with McKesson For i-Lid Cleanser Nov 17 2014
NovaBay Signs Distribution Agreement with McKesson for i-Lid Cleanser Nov 17 2014
10-Q for NovaBay Pharmaceuticals, Inc. Nov 14 2014
NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a Clinical/Business Update Nov 12 2014
NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a Clinical/Business Update Nov 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK